Patents by Inventor Andreas Pfeifer

Andreas Pfeifer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20100098707
    Abstract: The present invention is related to methods and compositions for the therapeutic and diagnostic use in the treatment of diseases and disorders which are caused by or associated with amyloid or amyloid-like proteins including amyloidosis, a group of disorders and abnormalities associated with amyloid protein such as Alzheimer's disease. The present invention provides novel methods and compositions comprising highly specific and highly effective antibodies having the ability to specifically recognize and bind to specific epitopes from a range of ?-amyloid proteins. The antibodies enabled by the teaching of the present invention are particularly useful for the treatment of diseases and disorders which are caused by or associated with amyloid or amyloid-like proteins including amyloidosis, a group of diseases and disorders associated with amyloid plaque formation including secondary amyloidosis and age-related amyloidosis including, but not limited to, neurological disorders such as Alzheimer's Disease (AD).
    Type: Application
    Filed: December 11, 2006
    Publication date: April 22, 2010
    Applicant: AC Immune S.A.
    Inventors: Ruth Greferath, David Hickman, Andreas Muhs, Andrea Pfeifer, Nicolau Claude
  • Publication number: 20100080800
    Abstract: The present invention is related to chimeric and humanized antibody and to methods and compositions for the therapeutic and diagnostic use in the treatment of amyloidosis, a group of disorders and abnormalities associated with amyloid protein such as Alzheimer's disease.
    Type: Application
    Filed: July 23, 2009
    Publication date: April 1, 2010
    Inventors: Andrea Pfeifer, Maria Pihlgren, Andreas Muhs, Ryan Watts
  • Publication number: 20090238840
    Abstract: The present invention is related to methods and compositions for the therapeutic and diagnostic use in the treatment of diseases and disorders which are caused by or associated with amyloid or amyloid-like proteins including amyloidosis. In particular, the present invention provides novel methods and compositions for eliciting a highly specific and highly effective immune response in an organism, but particularly within an animal, particularly a mammal or a human, which is capable of preventing or alleviating amyloidosis, or the symptoms associated with amyloidosis, a group of diseases and disorders associated with amyloid plaque formation including secondary amyloidosis and age-related amyloidosis including, but not limited to, neurological disorders such as Alzheimer's Disease (AD), including diseases or conditions characterized by a loss of cognitive memory capacity such as, for example, mild cognitive impairment (MCI).
    Type: Application
    Filed: April 14, 2009
    Publication date: September 24, 2009
    Applicant: AC Immune, S.A.
    Inventors: Andrea Pfeifer, Claude Nicolau
  • Publication number: 20090155249
    Abstract: The present invention is related to chimeric and humanized antibody and to methods and compositions for the therapeutic and diagnostic use in the treatment of amyloidosis, a group of disorders and abnormalities associated with amyloid protein such as Alzheimer's disease.
    Type: Application
    Filed: June 12, 2008
    Publication date: June 18, 2009
    Inventors: Andrea Pfeifer, Maria Pihlgren, Andreas Muhs, Ryan Watts
  • Publication number: 20090093002
    Abstract: The present invention is related to chimeric and humanized antibody and to methods and compositions for the therapeutic and diagnostic use in the treatment of amyloidosis, a group of disorders and abnormalities associated with amyloid protein such as Alzheimer's disease.
    Type: Application
    Filed: July 13, 2007
    Publication date: April 9, 2009
    Inventors: Andrea Pfeifer, Maria Pihlgren, Andreas Muhs, Ryan Watts
  • Publication number: 20090017041
    Abstract: The present invention is related to methods and compositions for the therapeutic and diagnostic use in the treatment of diseases and disorders which are caused by or associated with amyloid or amyloid-like proteins including amyloidosis, a group of disorders and abnormalities associated with amyloid protein such as Alzheimer's disease. The present invention provides novel methods and compositions comprising highly specific and highly effective antibodies having the ability to specifically recognize and bind to specific epitopes from a range of ?-amyloid proteins. The antibodies enabled by the teaching of the present invention are particularly useful for the treatment of diseases and disorders which are caused by or associated with amyloid or amyloid-like proteins including amyloidosis, a group of diseases and disorders associated with amyloid plaque formation including secondary amyloidosis and age-related amyloidosis including, but not limited to, neurological disorders such as Alzheimer's Disease (AD).
    Type: Application
    Filed: June 12, 2008
    Publication date: January 15, 2009
    Inventors: Andrea Pfeifer, Maria Pihlgren, Andreas Muhs, Ryan Watts
  • Publication number: 20090017040
    Abstract: The present invention is related to methods and compositions for the therapeutic and diagnostic use in the treatment of diseases and disorders which are caused by or associated with amyloid or amyloid-like proteins including amyloidosis, a group of disorders and abnormalities associated with amyloid protein such as Alzheimer's disease. The present invention provides novel methods and compositions comprising highly specific and highly effective antibodies having the ability to specifically recognize and bind to specific epitopes from a range of ?-amyloid proteins.
    Type: Application
    Filed: June 12, 2008
    Publication date: January 15, 2009
    Inventors: Andrea Pfeifer, Maria Pihlgren, Andreas Muhs, Ryan Watts
  • Publication number: 20080267986
    Abstract: The present invention is related to methods and compositions for the therapeutic and diagnostic use in the treatment of diseases and disorders which are caused by or associated with amyloid or amyloid-like proteins including amyloidosis. In particular, the present invention provides novel methods and compositions for eliciting a highly specific and highly effective immune response in an organism, but particularly within an animal, particularly a mammal or a human, which is capable of preventing or alleviating amyloidosis, or the symptoms associated with amyloidosis, a group of diseases and disorders associated with amyloid plaque formation including secondary amyloidosis and age-related amyloidosis including, but not limited to, neurological disorders such as Alzheimer's Disease (AD), including diseases or conditions characterized by a loss of cognitive memory capacity such as, for example, mild cognitive impairment (MCI).
    Type: Application
    Filed: December 12, 2006
    Publication date: October 30, 2008
    Inventors: Andrea Pfeifer, Claude Nicolau
  • Publication number: 20080166330
    Abstract: This invention relates to the treatment of atherosclerotic conditions through the inhibition of lipid oxidising abzymes by altering the composition of the intestinal microbial flora, for example by administering a bacterial composition to the individual. Suitable bacterial compositions may comprise, for example enteric bacteria such as lactobacilli spp, bifidobacteria spp, streptococcal spp and E. coli.
    Type: Application
    Filed: November 1, 2005
    Publication date: July 10, 2008
    Inventors: Ivan Petyaev, Andrea Pfeifer
  • Patent number: 7294509
    Abstract: This invention relates to new immortalized human pre-adipose cell lines capable of differentiating into adipose cells and methods of obtaing the immortalized cells. In particular, the present invention pertains to immortalized pre-adipocyte cell lines derived from white adipose tissue and methods of producing the cell lines. The immortalized pre-adipocyte cells are capable of maturing into immortalized white adipose cells useful in developing drugs, food ingredients and supplements against obesity, diabetes and cardiovascular diseases.
    Type: Grant
    Filed: January 21, 2003
    Date of Patent: November 13, 2007
    Assignee: Nestec S.A.
    Inventors: Christian Darimont, Katherine Mace, Andrea Pfeifer
  • Publication number: 20070166311
    Abstract: The present invention is related to methods and compositions for the therapeutic and diagnostic use in the treatment of diseases and disorders which are caused by or associated with amyloid or amyloid-like proteins including amyloidosis, a group of disorders and abnormalities associated with amyloid protein such as Alzheimer's disease. The present invention provides novel methods and compositions comprising highly specific and highly effective antibodies having the ability to specifically recognize and bind to specific epitopes from a range of ?-amyloid proteins. The antibodies enabled by the teaching of the present invention are particularly useful for the treatment of diseases and disorders which are caused by or associated with amyloid or amyloid-like proteins including amyloidosis, a group of diseases and disorders associated with amyloid plaque formation including secondary amyloidosis and age-related amyloidosis including, but not limited to, neurological disorders such as Alzheimer's Disease (AD).
    Type: Application
    Filed: December 11, 2006
    Publication date: July 19, 2007
    Inventors: Ruth Greferath, David Hickman, Andreas Muhs, Andrea Pfeifer, Claude Nicolau
  • Publication number: 20070071830
    Abstract: A primary composition that includes at least one lipophilic bioactive compound and a whey protein in an amount effective to increase the bioavailability of the lipophilic bioactive compound, and methods of forming the same. Also, an oral composition that contains the primary composition in a foodstuff, in a food supplement, in a cosmetic preparation or in a pharmaceutical preparation, and methods of forming the same.
    Type: Application
    Filed: October 27, 2006
    Publication date: March 29, 2007
    Inventors: Karlheinz Bortlik, Francoise Saucy, Eliane Duruz, Myriam Richelle, Pierre Lambelet, Markus Baur, Andrea Pfeifer
  • Publication number: 20050106219
    Abstract: The invention relates to a primary composition in which at least one lipophilic bioactive compound is mixed with a whey protein, present in an amount effective to increase the bioavailability of the lipophilic bioactive compound. The invention also relates to an oral composition that contains the primary composition in a foodstuff, in a food supplement, or in a pharmaceutical preparation, and to a cosmetic preparation that contains the primary composition. Methods for increasing the bioavailability of the lipophilic bioactive compound and providing increased photostability and oxidation resistance are also provided.
    Type: Application
    Filed: December 3, 2004
    Publication date: May 19, 2005
    Inventors: Karlheinz Bortlik, Francoise Saucy, Eliane Duruz, Myriam Richelle, Pierre Lambelet, Markus Baur, Andrea Pfeifer
  • Publication number: 20030175957
    Abstract: This invention relates to new immortalized human pre-adipose cell lines capable of differentiating into adipose cells and methods of obtaing the immortalized cells. In particular, the present invention pertains to immortalized pre-adipocyte cell lines derived from white adipose tissue and methods of producing the cell lines. The immortalized pre-adipocyte cells are capable of maturing into immortalized white adipose cells useful in developing drugs, food ingredients and supplements against obesity, diabetes and cardiovascular diseases.
    Type: Application
    Filed: January 21, 2003
    Publication date: September 18, 2003
    Applicant: NESTEC S.A.
    Inventors: Christian Darimont, Katherine Mace, Andrea Pfeifer
  • Patent number: 6399381
    Abstract: Human epithelial colon immortalized cell line, which does not express tumour markers, which expresses metabolic markers specific for the non-immortalized human epithelial cells and metabolic differentiation markers specific for the non-immortalized epithelial cells of the human colon, and which is capable of adhering in vitro to the strain of lactic acid bacterium CNCM-1225. Serum-free culture medium characterized in that it comprises trace elements, vitamins consisting of vitamin C and retinoic acid, and hormones consisting of triiodothyronine, dexamethasone, hydrocortisone, bovine pituary gland extract, insulin, EGF and transferrin. Process for the immortalization of epithelial cells of the human colon, in which a culture of primary epithelial cells derived from the human colon is prepared, the culture is infected with a recombinant virus, the immortalized cells are cultured in the serum-free culture medium according to the invention.
    Type: Grant
    Filed: June 14, 2000
    Date of Patent: June 4, 2002
    Assignee: Nestac S.A.
    Inventors: Stéphanie Blum, Andrea Pfeifer, Yvonne Tromvoukis
  • Patent number: 6395542
    Abstract: Human epithelial colon immortalized cell line, which does not express tumour markers, which expresses metabolic markers specific for the non-immortalized human epithelial cells and metabolic differentiation markers specific for the non-immortalized epithelial cells of the human colon, and which is capable of adhering in vitro to the strain of lactic acid bacterium CNCM-1225. Serum-free culture medium characterized in that it comprises trace elements, vitamins consisting of vitamin C and retinoic acid, and hormones consisting of triiodothyronine, dexamethasone, hydrocortisone, bovine pituary gland extract, insulin, EGF and transferrin. Process for the immortalization of epithelial cells of the human colon, in which a culture of primary epithelial cells derived from the human colon is prepared, the culture is infected with a recombinant virus, the immortalized cells are cultured in the serum-free culture medium according to the invention.
    Type: Grant
    Filed: June 14, 2000
    Date of Patent: May 28, 2002
    Assignee: Nestec S.A.
    Inventors: Stéphanie Blum, Andrea Pfeifer, Yvonne Tromvoukis
  • Publication number: 20020012993
    Abstract: The present invention relates to improved continuous (immortalized) cell lines, in particular keratinocytes and melanocytes derived from normal human skin tissue. The present invention also relates to novel serum-free media for isolating, producing and maintaining said improved continuous keratinocyte and melanocyte cell lines. The present invention also relates to methods for producing primary melanocytes and keratinocytes under serum-free conditions without any feeder cells.
    Type: Application
    Filed: June 19, 1998
    Publication date: January 31, 2002
    Inventors: MARKUS BAUR, CATHERINE MACE, ARMAND MALNOE, ANDREA PFEIFER, MARCELLE REGNIER
  • Patent number: 6194203
    Abstract: Immortalized adult human colon epithelial cell line, which does not express tumour markers, which expresses metabolic markers specific for the non-immortalized human epithelial cells and metabolic differentiation markers specific for the non-immortalized epithelial cells of the human colon, and which is capable of adhering in vitro to the strain of lactic acid bacterium CNCM-1225. Serum-free culture medium characterized in that it comprises trace elements, vitamins consisting of vitamin C and retinoic acid, and hormones consisting of triiodothyronine, dexamethasone, hydrocortisone, bovine pituary gland extract, insulin, EGF and transferrin. Process for the immortalization of epithelial cells of the human colon, in which a culture of primary epithelial cells derived from the human colon is prepared, the culture is infected with a recombinant virus, the immortalized cells are cultured in the serum-free culture medium according to the invention.
    Type: Grant
    Filed: April 17, 1997
    Date of Patent: February 27, 2001
    Assignee: Nestec S.A.
    Inventors: Stéphanie Blum, Andrea Pfeifer, Yvonne Tromvoukis